HYRIMOZ(CF) PEN PSORIASIS (adalimumab-adaz)
ANTIPSORIATICS · CROHN'S DISEASE ·+8
SANDOZ
Drug class
Antirheumatic Agents (Biologic DMARDS)
Antirheumatic agents classified as biologic disease-modifying antirheumatic drugs (bDMARDs) are genetically engineered, protein-based immunomodulatory therapies designed to arrest underlying disease progression and prevent structural joint damage. Read more about Antirheumatic Agents (Biologic DMARDS)
170 drugs in this class 49 manufacturers
Drugs in Antirheumatic Agents (Biologic DMARDS)
ADALIMUMAB-AACF(CF) (adalimumab-aacf)
ANTIPSORIATICS · CROHN'S DISEASE ·+8
FRESENIUS KABI
ADALIMUMAB-AACF(CF) (2 PK) (adalimumab-aacf)
ANTIPSORIATICS · CROHN'S DISEASE ·+8
FRESENIUS KABI
ADALIMUMAB-AACF(CF) PEN (2 PK) (adalimumab-aacf)
ANTIPSORIATICS · CROHN'S DISEASE ·+8
FRESENIUS KABI
ADALIMUMAB-AACF(CF) PEN CROHNS (adalimumab-aacf)
ANTIPSORIATICS · CROHN'S DISEASE ·+8
FRESENIUS KABI
ADALIMUMAB-AACF(CF) PEN PS-UV (adalimumab-aacf)
ANTIPSORIATICS · CROHN'S DISEASE ·+8
FRESENIUS KABI
TOFIDENCE (tocilizumab-bavi)
MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 6 INHIBITORS · GIANT CELL ARTERITIS ·+5
BIOGEN/ORGANON
XELJANZ (tofacitinib citrate)
INFLAMMATORY BOWEL AGENTS · ULCERATIVE COLITIS ·+4
U.S. PHARMACEUT
ADALIMUMAB-AATY(CF) AI CROHNS (adalimumab-aaty)
ANTIPSORIATICS · CROHN'S DISEASE ·+8
CELLTRION USA,
Filter & compare in the drug finder →
Opens the drug finder with Antirheumatic Agents (Biologic DMARDS) preselected. Add indication or manufacturer filters there.
Antirheumatic agents classified as biologic disease-modifying antirheumatic drugs (bDMARDs) are genetically engineered, protein-based immunomodulatory therapies designed to arrest underlying disease progression and prevent structural joint damage.
Unlike broad-spectrum conventional synthetic DMARDs, bDMARDs selectively target specific inflammatory cytokines, cell-surface markers, or costimulatory pathways, including tumor necrosis factor-alpha, interleukins, and B-cell or T-cell activation mechanisms.
They are principally indicated for moderate-to-severe inflammatory autoimmune conditions, most notably rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis, particularly when conventional therapies fail to provide adequate disease control.
-
nih.gov
Antirheumatic agents classified as biologic disease-modifying antirheumatic drugs (bDMARDs) are genetically engineered, protein-based immunomodulatory therapies designed to arrest underlying disease progression and prevent structural joint damage Unlike broad-spectrum conventional synthetic DMARDs, bDMARDs selectively target specific inflammatory cytokines, cell-surface markers, or costimulatory pathways, including tumor necrosis factor-alpha, interleukins, and B-cell or T-cell activation mechan...
-
fda.gov
Antirheumatic agents classified as biologic disease-modifying antirheumatic drugs (bDMARDs) are genetically engineered, protein-based immunomodulatory therapies designed to arrest underlying disease progression and prevent structural joint damage
-
wv.gov
Unlike broad-spectrum conventional synthetic DMARDs, bDMARDs selectively target specific inflammatory cytokines, cell-surface markers, or costimulatory pathways, including tumor necrosis factor-alpha, interleukins, and B-cell or T-cell activation mechanisms They are principally indicated for moderate-to-severe inflammatory autoimmune conditions, most notably rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis, particularly when conventional therap...
-
clevelandclinic.org
They are principally indicated for moderate-to-severe inflammatory autoimmune conditions, most notably rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis, particularly when conventional therapies fail to provide adequate disease control
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.